玻璃体腔注射雷珠单抗治疗病理性近视脉络膜新生血管  

Efficacy of intravitreal Ranibizumab injection for choroidal neovascularization secondary to pathologic myopia

作　　者：崔丽红[1] 杨智[1] 徐丽[1] 

机构地区：[1]中国辽宁省沈阳市第四人民医院眼科,110031

出　　处：《国际眼科杂志》2016年第3期526-528,共3页International Eye Science

摘　　要：目的：观察玻璃体腔注射雷珠单抗治疗病理性近视脉络膜新生血管（CNV）的临床疗效和安全性。方法：回顾分析临床确诊为病理性近视CNV患者24例25眼,所有患者行ETDRS视力表检查、前置镜下眼底检查、荧光素眼底血管造影（FFA）、吲哚菁绿血管造影（ICGA）、光学相干断层扫描（OCT）检查。所有患者按照常规内眼手术操作要求玻璃体腔内注射10mg/m L雷珠单抗0.05m L,随访4~10mo。观察比较治疗前后最佳矫正视力（BCVA）、黄斑中心凹视网膜厚度（CMT）。结果：所有患者均未出现与治疗相关的局部和全身并发症。平均治疗次数为1.52次。治疗前最佳矫正视力（BCVA）平均23.93±12.46个字母;末次随访BCVA平均40.63±7.25个字母,较治疗前提高14.27±9.36个字母,差异有统计学意义（t=5.74,P〈0.05）。治疗前CMT平均363.47±119.62μm,末次随访平均CMT为190.31±37.02μm,较治疗前下降72.82±60.57μm,差异有统计学意义（t=3.96,P〈0.05）。结论：玻璃体腔注射雷珠单抗治疗病理性近视CNV是安全有效的,有利于提高患者视力,减轻视网膜水肿,停止或减少病灶的渗漏。AIM：To observe the efficacy and safety of intravitreal Ranibizumab injection in patiens with choroidal neovascularization（CNV） secondary to pathologic myopia.·METHODS：In this retrospective and comparative study,24 patients（25 eyes） with CNV secondary to pathologic myopia were enrolled.All patients were assessed by examinations of ETDRS visual acuity chart,preplacedmirror ophthalmoscopy,fundus fluorescein angiography（FFA）,indocyanine green angiography（ICGA） and optical coherence tomography（OCT）.Patiens received intravitreally injected ranibizumab 0.5mg（0.05mL）.Treatments were repeated if the follow-up indicated that it was necessary.The follow-up periods were 4~10mo.Best corrected visual acuity（BCVA）,central macular thickness（CMT） and leakage of CNV before and after the treatment were compared.·RESULTS：No local or systemic complications occurred in any patients during the treatment or follow-up.The average time of injection was 1.52.The mean BCVA was23.93±12.46 letters before the therapy.In the last followup,the mean BCVA was 40.63±7.25 letters,improved by14.27 ± 9.36 letters and the difference was statically significant（t=5.74,P0.05）.The mean CMT was 363.47±119.62μm before treatments and 190.31±37.02μm after treatments which was 72.82±60.57μm less than the pretreatment values and the difference was statically significant（t=3.96,P0.05）.·CONCLUSION：Intravitreal ranibizumab injection for CNV secondary to pathologic myopia is safe and effective,and this treatment can improve visual acuity,reduce retina edema and leakage of CNV.

关 键 词：脉络膜新生血管化 药物疗法 近视 退行性 抗体 单克隆 

分 类 号：R778.11[医药卫生—眼科]